PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights PART 05: Pipeline portfolio PART 06: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 07: Market segmentation by disease type PART 08: Global CLL therapeutics market • Market overview • Total addressable market for global CLL therapeutics • Vendors in the market PART 09: Global ALL therapeutics market • Market overview • Vendors in the market PART 10: Global AML therapeutics market • Market overview • Vendors in the market PART 11: Global CML therapeutics market • Market overview • Vendors in the market PART 12: Geographical segmentation • Global leukemia therapeutics market by geography 2015-2020 • Leukemia therapeutics market in Americas • Leukemia therapeutics market in EMEA • Leukemia therapeutics market in APAC PART 13: Market drivers • Special regulatory designations for drugs • Technological advances in the monitoring of leukemia • Application for expanded indication approvals PART 14: Impact of drivers PART 15: Market challenges • Complicated disease prognosis • Financial and infrastructural constraints • Limitations associated with current therapeutic options • Delay in diagnosis PART 16: Impact of drivers and challenges PART 17: Market trends • Rise in the development of combination therapies • Patient assistance programs • Focus on the identification of targets for the development of new therapies PART 18: Vendor landscape • Competitive scenario • Other prominent vendors PART 19: Key vendor analysis • F. Hoffmann-La Roche • Novartis • Bristol-Myers Squibb • AbbVie • Teva Pharmaceuticals PART 20: Appendix • List of abbreviations PART 21: Explore TechnavioList of Exhibits Exhibit 01: Product offerings Exhibit 02: Timeline of development of leukemia drugs Exhibit 03: Impact of key customer segments on market 2015 Exhibit 04: Key buying criteria for global leukemia therapeutics market 2015 Exhibit 05: Pipeline portfolio: Global CLL therapeutics market Exhibit 06: Pipeline portfolio: Global CML therapeutics market Exhibit 07: Pipeline portfolio: Global ALL therapeutics market Exhibit 08: Pipeline portfolio: Global AML therapeutics market Exhibit 09: Global leukemia therapeutics market snapshot: Developed and emerging markets 2015 Exhibit 10: Distribution of people aged 60 years and over (millions) Exhibit 11: Global leukemia therapeutics market 2015-2020 ($ billions) Exhibit 12: Global leukemia therapeutics market segmentation: Growth cycle analysis Exhibit 13: Five forces analysis Exhibit 14: Segmentation of global leukemia therapeutics market by type of disease 2015 Exhibit 15: Global leukemia therapeutics market by type of disease 2015-2020 Exhibit 16: Global leukemia therapeutics market segmentation: Growth lifecycle analysis Exhibit 17: Global CLL therapeutics market 2015-2020 ($ billions) Exhibit 18: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions) Exhibit 19: Major vendors in the CLL therapeutics market 2015 Exhibit 20: Global ALL therapeutics market 2015-2020 ($ billions) Exhibit 21: Major vendors in ALL therapeutics market 2015 Exhibit 22: Global AML therapeutics market 2015-2020 ($ millions) Exhibit 23: Major vendors in global AML therapeutics market Exhibit 24: Global CML therapeutics market 2015-2020 ($ billions) Exhibit 25: Major vendors in global CML therapeutics market Exhibit 26: Global leukemia therapeutics market by geography 2015-2020 Exhibit 27: Percentage share of global leukemia therapeutics market by geography 2015 and 2020 Exhibit 28: Global share of leukemia therapeutics market by geography 2015 Exhibit 29: Revenue of global leukemia therapeutics market by geography 2015-2020 ($ billions) Exhibit 30: Revenue/growth outlook in different countries/regions 2015 Exhibit 31: Global leukemia therapeutics market segmentation by region: Market growth lifecycle analysis 2015 Exhibit 32: Leukemia therapeutics market in different regions by type of disease Exhibit 33: Opportunity analysis of leukemia therapeutics market in Americas Exhibit 34: Percentage share of new cases of leukemia in US 2014 Exhibit 35: Hispanic population percentage in US total population Exhibit 36: Leukemia therapeutics market in Americas 2015-2020 ($ billions) Exhibit 37: Opportunity analysis of leukemia therapeutics market in EMEA Exhibit 38: Leukemia therapeutics market in EMEA 2015-2020 ($ billions) Exhibit 39: Opportunity analysis of leukemia therapeutics market in APAC Exhibit 40: Leukemia therapeutics market in APAC 2015-2020 ($ billions) Exhibit 41: Orphan designation pipeline drugs for leukemia Exhibit 42: Breakthrough therapy designation drugs for leukemia Exhibit 43: Expanded indication approval drugs in the treatment of leukemia Exhibit 44: Impact of drivers Exhibit 45: Cost of therapy for some leukemia drugs Exhibit 46: Impact of drivers and challenges Exhibit 47: Combination therapies under development for the treatment of leukemia Exhibit 48: Leukemia drugs with patient assistance programs Exhibit 49: Key vendors ranking 2015 Exhibit 50: Geographical presence of key vendors in leukemia therapeutics market 2015 Exhibit 51: Competitive landscape of vendors in global leukemia therapeutics market 2015-2020 Exhibit 52: F. Hoffmann-La Roche: Profile Exhibit 53: F. Hoffmann-La Roche: Strength analysis Exhibit 54: F. Hoffmann-La Roche: Growth strategy matrix Exhibit 55: F. Hoffmann-La Roche: Opportunity assessment Exhibit 56: F. Hoffmann-La Roche: YoY revenue and growth rate of Rituxan/MabThera 2013-2015 ($ billions) Exhibit 57: F. Hoffmann-La Roche: Rituxan/MabThera geographic segmentation by revenue 2015 Exhibit 58: Novartis: Profile Exhibit 59: Novartis: Strength analysis Exhibit 60: Novartis: Growth strategy matrix Exhibit 61: Novartis: Opportunity assessment Exhibit 62: Bristol-Myers Squibb: Profile Exhibit 63: Bristol-Myers Squibb: Strength analysis Exhibit 64: Bristol-Myers Squibb: Growth strategy matrix Exhibit 65: Bristol-Myers Squibb: Opportunity assessment Exhibit 66: AbbVie: Profile Exhibit 67: AbbVie: Strength analysis Exhibit 68: AbbVie: Growth strategy matrix Exhibit 69: AbbVie: Opportunity assessment Exhibit 70: Teva Pharmaceuticals: Profile Exhibit 71: Teva Pharmaceuticals: Strength analysis Exhibit 72: Teva Pharmaceuticals: Growth strategy matrix Exhibit 73: Teva Pharmaceuticals: Opportunity assessment Exhibit 74: Teva Pharmaceuticals: YoY revenue and growth rate of TREANDA 2013-2015 ($ millions)

F. Hoffmann-La Roche, Novartis, Bristol-Myers Squibb, AbbVie, Teva Pharmaceuticals, Altor BioScience, Amgen, ARIAD Pharmaceuticals, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Baxter Healthcare, Bayer HealthCare, Bellicum Pharmaceuticals, Biogen, Boehringer Ingelheim, BioLineRx, Boston Biomedical, Celator Pharmaceuticals, Celgene, CTI BioPharma, Chroma Therapeutics, Chugai Pharmaceutical, Cyclacel Pharmaceuticals, Daiichi Sankyo, Eisai, Emergent BioSolutions, Erytech Pharma, Fate Therapeutics, Genzyme, Gilead Sciences, GlaxoSmithKline, iDD biotech, Immune Pharmaceuticals, Immunomedics, Infinity Pharmaceuticals, Innate Pharma, Jazz Pharmaceuticals, Juno Therapeutics, Karyopharm Therapeutics, Ligand Pharmaceuticals, MEDA Pharmaceuticals, MedImmune, Merck, Midas Pharma, Molecular Templates, MorphoSys, Nippon Shinyaku, Novo Nordisk, Onconova Therapeutics, Ono Pharmaceuticals, Orphan Europe, Otsuka, Pfizer, Portola Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sigma-Tau Pharmaceuticals, Stemline Therapeutics, Sunesis Pharmaceuticals, TG Therapeutics, TheraMAB, Tolero Pharmaceuticals, XEME Biopharma, Xencor, and ZIOPHARM Oncology.